A case of JAK2V617F-positive essential thrombocythemia where allele burden was reduced by a PD-1 inhibitor-Reference-Cited by-同舟云学术

A case of JAK2V617F-positive essential thrombocythemia where allele burden was reduced by a PD-1 inhibitor

Published:2021-01-03 Issue:4 Volume:113 Page:606-610
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Hara Ryujiro^ORCID,Kawada Hiroshi,Kikuti Yara Yukie,Kikkawa Eri,Harada Kaito,Aoyama Yasuyuki,Ogiya Daisuke,Toyosaki Masako,Suzuki Rikio,Machida Sinichiro,Ohmachi Ken,Onizuka Makoto,Ogawa Yoshiaki,Masuda Ryota,Iwazaki Masayuki,Nakamura Naoya,Ando Kiyoshi

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/content/pdf/10.1007/s12185-020-03046-x.pdf

Reference25 articles.

1. Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124:2507–13.

2. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–39.

3. Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856–67.

4. Prestipino A, Emhardt AJ, Aumann K, O’Sullivan D, Gorantla SP, Duquesne S, et al. Oncogenic JAK2(V617F) causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. Sci Transl Med. 2018;10:eaam7729.

5. Hadzijusufovic E, Keller A, Berger D, Greiner G, Wingelhofer B, Witzeneder N, et al. STAT5 is expressed in CD34(+)/CD38(-) stem cells and serves as a potential molecular target in ph-negative myeloproliferative neoplasms. Cancers (Basel). 2020;12:1021.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial;Frontiers in Immunology;2023-02-23

2. Essential thrombocythaemia progression to the fibrotic phase is associated with a decrease in JAK2 and PDL1 levels;Annals of Hematology;2022-10-21

3. Antineoplastics;Reactions Weekly;2021-07